VIFOR PHARMA INVESTOR PRESENTATION
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
VIFOR PHARMA INVESTOR PRESENTATION January 2020
VIFOR PHARMA
OUR VISION
Global leader
in iron deficiency, nephrology
and cardio-renal therapies.
© Vifor Pharma January 2020 2
EXPERIENCED LEADERSHIP TEAM
PROVEN TRACK RECORD
ETIENNE JORNOD STEFAN SCHULZE COLIN BOND
EXECUTIVE CHAIRMAN PRESIDENT OF THE EXECUTIVE CHIEF FINANCIAL OFFICER
OF THE BOARD OF DIRECTORS COMMITTEE & COO
© Vifor Pharma January 2020 3
PROVEN TRACK RECORD
CORPORATE TIMELINE AND STRATEGY
2020
2015
2010
2000 BECOMING GLOBAL LEADER
IN NEPHROLOGY AND ENTERING
BECOMING GLOBAL LEADER
CARDIO-RENAL DISEASE AREA
BUILDING IRON PORTFOLIO IN IRON DEFICIENCY AND
AND INTERNATIONAL EXPANSION ENTERING INTO NEPHROLOGY • 2015: Mircera® license
• 2000: Venofer® US FDA approval • 2015: Veltassa® license
• 2010: Creation of VFMCRP • 2016: Four in-licensing deals
• 2007: Launch of Ferinject®
• 2013: Injectafer® – FDA approval • 2016: Relypsa acquisition
• 2008: Acquisition Aspreva
• 2013: Launch of Velphoro® • 2017: Galenica Santé IPO
• 2008: Creation of EU affiliates
• 2009: Acquisition OM Pharma • 2017: Vadadustat1) license
• 2018: CR8451) license
• 2019: Invokana® co-promotion
• 2019: Joint venture with Evotec
1) Pre-commercial products
© Vifor Pharma January 2020 4LEADING PORTFOLIO IN TARGET THERAPY AREAS
Iron
Nephrology Cardio-renal
deficiency
Own
products
In-licensed
products Rayaldee®1) CR8451)
Vadadustat1) Avacopan1) CCX1401)
1) Pre-commercial products
© Vifor Pharma January 2020 5THREE STRATEGIC GROWTH DRIVERS
Ferinject®
Exploit the potential through market awareness
Nephrology (VFMCRP1))
Expand leadership position
Veltassa®
Build a blockbuster
1) Vifor Fresenius Medical Care Renal Pharma
© Vifor Pharma January 2020 6FERINJECT®
GLOBAL LEADER IN THE I.V. IRON MARKET
[T
1996 2019
23%
28%
81 1’991
CHFm CHFm
50%
Source: quarterly IQVIATM MIDAS® panel, GERS, Insight Health, DLI, MAT Q2-2019, historical data at constant exchange rate (average 2018)
© Vifor Pharma January 2020 7FERINJECT®
BLOCKBUSTER STATUS ALREADY REACHED IN 2019
IN-MARKET SALES1)
CHF MILLION
>1’000
898
698
540
379
244
191
83 126
16 39 59
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Launch in FAIR-HF FERGI-COR PREFER study FIND-CKD CONFIRM- New EU New ESC Intensifying
CH, UK, study study (fatigue) study (ND- HF study onco guidelines promotional
Spain (cardio) (gastro) CKD) (cardio) guidelines (cardio) effort by
New EU
Daiichi
guidelines: Injectafer® EFFECT-HF
Sankyo
nephro, cardio, approved study
gastro, onco in the USA (cardio)
Europe US RoW
1) Based on quarterly IQVIATM MIDAS® panel, GERS, Insight Health, DLI, historical data at constant exchange rate (average 2018)
© Vifor Pharma January 2020 8FERINJECT®
SIGNIFICANT MARKET OPPORTUNITY REMAINS 1)
Ferinject® in-market volume growth Ferinject® volume per capita2)
Launch Date
2% Switzerland 248 2008
16% Australia 114 2011
37% Spain 41 2009
11% Sweden 39 2008
11% Germany 36 2007
45% Italy 33 2012
22% UK 26 2008
29% U.S. 16 2013
0% Japan 0 20203)
0% China 0 2021
1) Based on quarterly IQVIATM MIDAS® panel, GERS, Insight Health, moving annual total (MAT) Q2 2018-19, historical data at constant exchange rate (average 2018)
2) 100 mg eq./1’000 population 3) Subject to reimbursement
© Vifor Pharma January 2020 9FERINJECT®
EXPLOIT THE POTENTIAL
2020 2021 2022 2023 2024 2025
Geographic Japan launch1) China launch
expansion 2020 2021 > CHF 2
billion
in-market
AFFIRM-AHF FAIR-HF2 HEART-FID U.S. label sales
Life cycle completion* completion*2) completion*3) (> CHF 1
update
management Post-approval Post-approval U.S. Post- billion
study study approval study
reported
sales)
Indications
with high Focus on heart failure, patient blood management and nephrology
unmet need
*Targeted guidelines:
1) Subject to reimbursement 2) Investigator initiated study, University of Hamburg 3) Study conducted by our US partner Daiichi Sankyo
© Vifor Pharma January 2020 10NEPHROLOGY
HIGHLY DIVERSIFIED PORTFOLIO
ANAEMIA MINERAL & BONE KIDNEY CKD-ASSOCIATED
MANAGEMENT MANAGEMENT PROTECTION COMPLICATIONS
Rayaldee®1) Avacopan1) CR8451)
CCX1401)
Vadadustat1)
1) Pre-commercial products
© Vifor Pharma January 2020 11NEPHROLOGY
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA
55% Stake
STRONG IRON AND PHARMA EXPERTISE
Rayaldee®1)
CCX1401)
Avacopan1)
CR8451) Vadadustat1)
GLOBAL LEADER IN DIALYSIS
45% Stake
1) Pre-commercial products
© Vifor Pharma January 2020 12NEPHROLOGY
DELIVERING INNOVATION TO NEPRHOLOGY PATIENTS
2020 2020 2021 2022 2023 2024 2025
Rayaldee® Avacopan & CCX140 > CHF 1bn
launch CR845 launch launch reported sales
CR845 Vadadustat
Additional launches in nephrology
Ph. III data launch
Vadadustat CCX140
Ph. III data Ph. II data
Early stage development through the joint venture with Evotec
© Vifor Pharma January 2020 13NEPHROLOGY
NUMEROUS OPPORTUNITIES REMAIN
CURRENT INDICATIONS PIPELINE INDICATIONS POTENTIAL INDICATIONS
Hypernatremia
FSGS Vascular calcification
Iron deficiency
Polycystic kidney disease
Anaemia ANCA associated vasculitis
Kidney stones Kidney fibrosis
Diabetic kidney disease Secondary hyperparathyroidism
Hyperphosphatemia β-Thalassemia renal disease
Uremic pruritus
Hyperkalemia Metabolic acidosis aHUS
C3G
Acute kidney injury
Fabry
© Vifor Pharma January 2020 14NEPHROLOGY
LEADERSHIP OF THE WHOLE NEPHROLOGY CHAIN
PRE-CLINICAL CLINICAL / PRE-COMMERCIAL
PARTNERSHIP IN-LICENSING DEALS AND PARTNERSHIPS
Avacopan Rayaldee®
DATA GENERATION
Joint venture CCX140
with Evotec CR845 Vadadustat
COMMERCIAL
PRE-DIALYSIS DIALYSIS TRANSPLANTATION
© Vifor Pharma January 2020 15NEPHROLOGY
LEVERAGING US COMMERCIAL ORGANISATION
Invokana®
• First new treatment of diabetic kidney
disease in more than 20 years
+ • Royalties received on net sales
• Targeted population of 1.2 million
• Accretive latest end of 2020
US nephrologists
© Vifor Pharma January 2020 16NEPHROLOGY
AVACOPAN POSITIVE PHASE-III TRIAL RESULTS
Avacopan
Improve renal function
• Week 26: BVAS1) remission
• Week 52: statistically superior
• Improved quality of life
Standard of care
• Increased risk of mortality
• High risk of infections
• Irreversible kidney damage
Reduce glucocorticoid toxicity
1) Birmingham Vasculitis Activity Score
© Vifor Pharma January 2020 17NEPHROLOGY
ADDING WORLD CLASS PRE-CLINICAL CAPABILITIES
[]
50%
Joint venture Pre-clinical candidates
50%
© Vifor Pharma January 2020 18NEPHROLOGY
STAGED, SUCCESS DEPENDENT PARTNERSHIP
[]
Joint venture
Generate target candidates Pre-clinical up to phase II Phase III to commercialisation
• World class discovery • Combines respective expertise • Global commercial network
• Unique kidney biobank • Joint scientific committee • Unique access to nephrology patients
© Vifor Pharma January 2020 19VELTASSA®
BUILDING THE HYPERKALAEMIA MARKET
[]
2015 2019
• Calcium-based, non-absorbed
• Limited undesirable effects
• 52-weeks data available
175 295 46%
CHFm • RAASi enabling feature included in
54% CHFm
SmPC1) in Europe
• Acute & chronic usage
• Room temperature storage
Source: quarterly IQVIATM MIDAS® panel, GERS, Insight Health, DLI, MAT Q2-2019, historical data at constant exchange rate (average 2018) 1) SmPC = summary of product characteristics
© Vifor Pharma January 2020 20VELTASSA®
ASSESSMENT OF LONG TERM POTENTIAL UNCHANGED
US MARKET OPPORTUNITY
3 million x USD 820 x 6 months = > USD 10 billion
Estimated Monthly gross price Targeted duration Potential market size
hyperkalaemia patients of treatment (net sales)
© Vifor Pharma January 2020 21VELTASSA®
DRIVE TO BLOCKBUSTER STATUS
2020 2020 2021 2022 2023 2024 2025
European rollout Japan launch Blockbuster
Zeria status
Guideline* DIAMOND Guideline*
updates based on completion updates based on
AMBER results Post-approval study DIAMOND results
Label updates based on
DIAMOND results
*Targeted guidelines:
© Vifor Pharma January 2020 22R&D INVESTMENTS
FOCUS IS ON KEY PRODUCTS AND CLINICAL PIPELINE
PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 LIFE CYCLE MANAGEMENT
AFFIRM-AHF
(2020)
Own Joint venture Oral ferroportin HEART FID
Products with Evotec inhibitor1) (2022)2)
DIAMOND
(2022)
CR845
(Q2 2020)
In-licensed
Products CCX140
(2020)
Vadadustat
(Q2 2020)
1) Iron overload; leveraging iron metabolism expertise 2) Study conducted by our US partner Daiichi Sankyo
© Vifor Pharma January 2020 23GUIDANCE 2019
NET SALES AND EBITDA GUIDANCE INCREASED
In 2019 at constant exchange rates, Vifor Pharma net sales are expected to exceed 15%,
reported EBITDA is expected to grow between 25% and 30%.
In 2020 net sales are expected to exceed CHF 2 billion and
EBITDA to be in the range of CHF 700 million.
Going forward the dividend is expected to remain at the current level of CHF 2 per share.
© Vifor Pharma January 2020 24OUTLOOK 2020
Ferinject® launch in Japan, subject to reimbursement
MARKET ACCESS Go-to-market strategy in China for Ferinject®
Filing of Avacopan in Europe
Ferinject® phase-IV AFFIRM-AHF study readout (H2 2020)
CR-845 phase-III KALM-2 study readout (Q2 2020)
CLINICAL TRIALS
Vadadustat phase-III INNO2VATE studies readout (Q2 2020)
CCX140: LUMINA-1 and LUMINA-2 phase-II studies readout
BUSINESS
At least one additional in-licensing, product acquisition or corporate transaction
DEVELOPMENT
© Vifor Pharma January 2020 25CONTACT INFORMATION
Colin Bond – CFO
Phone: +41 58 851 83 53
Email: colin.bond@viforpharma.com
INVESTOR RELATIONS
Julien Vignot – Head of Investor Relations
Phone: +41 58 851 66 90
Email: julien.vignot@viforpharma.com
Laurent de Weck – Investor Relations Manager
Phone: +41 58 851 80 95
Email: laurent.deweck@viforpharma.com
© Vifor Pharma January 2020 26DISCLAIMER Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company’s or, as appropriate, the Company’s directors’ current expectations and projections about future events. By their nature, forward- looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this presentation as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its of their parent or subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. You should not place undue reliance on forward- looking statements, which speak only as of the date of this presentation. © Vifor Pharma January 2020 27
You can also read
